



# CANCER RESEARCH & ONCOLOGY

SEPTEMBER 30 - OCTOBER 01, 2015

Date	Time	Track	Presentation Title	Speaker
30-Sep	06:00 - 07:00 AM	Industry Speaker	Comparative genome and transcriptome analysis of small cell numbers	Christian Korfhage, PhD Director, Scientific Applications: NGS & Isothermal Amplifications, QIAGEN
30-Sep	06:00 - 07:00 AM	Prostate Cancer Mini-symposium	Keynote Presentation: What's New and in the News with Prostate Cancer 2015	Judd W Moul, MD, FACS James H Semans MD Professor of Surgery, Division of Urologic Surgery, Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center
30-Sep	07:30 - 08:30 AM	Prostate Cancer Mini-symposium	How do I choose? Androgen Biosynthesis Inhibitor, Androgen Receptor Antagonist, or both for treatment of mCRPC?	Lawrence Karsh MD FACS Director of Research, CPI & Attending Urologist, The Urology Center of Colorado
30-Sep	07:30 - 08:30 AM	Innovations in Cancer Immunotherapy	Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics	Brian Soper, PhD Technical Information Scientist, The Jackson Laboratory
30-Sep	07:30 - 08:30 AM	Targeted, precision therapies for advanced disease	Ligand-Targeted Therapies for Cancer and Autoimmune Diseases	Philip S. Low, PhD Director of the Purdue Center for Drug Discovery Ralph C. Corley Distinguished Professor Department of Chemistry, Purdue University
30-Sep	09:00 - 10:00 AM	Prostate Cancer Mini-symposium	Inventing Active Surveillance version 2.0	Eric Klein, MD Chairman of the Glickman Urological & Kidney Institute, Cleveland Clinic
30-Sep	09:00 - 10:00 AM	Cancer Metabolism	Lactate-driven metabolic adaptation modulates breast cancer progression	Jennifer Molina, PhD Institute Research Scientist, Institute for Applied Cancer Science at MD Anderson Cancer Center

30-Sep	10:30 - 11:30 AM	Prostate Cancer Mini-Symposium	The Evolving Role of Image-Guided Prostate Cancer Targeting and Ablation: Moving Towards Personalized Medicine	Rajan Gupta, MD Assistant Professor of Radiology, Director, Abdominal Imaging Fellowship Program, Duke University School of Medicine Thomas Polascik, MD Professor of Surgery, Director, Society of Urologic Oncology Program, Director, Genitourinary Program on Focal Therapy, Duke Cancer Institute, Duke University Medical Center Stacy Loeb, MD Assistant Professor of Urology and Population Health, NYU School of Medicine
30-Sep	12:00 - 01:00 PM	Prostate Cancer Mini-symposium	Keynote Presentation: What's New in Robotics and minimally invasive therapy for prostate cancer and prostate disease	David Albala, MD Chief of Urology at Crouse Hospital and Medical Director for Associated Medical Professionals Herbert Lepor, MD Urologist, NYU Langone Medical Center
30-Sep	12:00 - 01:00 PM	Innovations in cancer immunotherapy	Modeling and dissecting hepatocellular carcinoma dissemination	Brian Lewis, PhD Associate Professor, Molecular, Cell and Cancer Biology, University of Massachusetts Medical School
30-Sep	01:30 - 02:30 PM	Targeted, precision therapies for advanced disease	Biomarkers: An Auspicious Beginning and a Portentous Future?	Anna Barker, PhD Co-Director, Complex Adaptive Systems Initiative, Director, Transformative Healthcare Networks, Professor, School of Life Sciences, Arizona State University (ASU)
30-Sep	01:30 - 02:30 PM	Industry Speaker	Role of microRNA-mRNA interactions in Endometrioid Endometrial Carcinoma, a "Sample to Insight" biological exploration	Jean-Noel Billaud, PhD Senior Principal Scientist, QIAGEN Digital Insights
30-Sep	01:30 - 02:30 PM	Progress in detection of rare cancer mutations and Implications for treatment	SuperSelective Primers for the Multiplex Quantitation of Rare Mutant Sequences Associated with Cancer	Fred Kramer, PhD Professor, Public Health Research Institute, New Jersey Medical School, Rutgers University
1-Oct	06:00 - 07:00 AM	The "Liquid Biopsy" : applications for blood-based noninvasive cancer diagnostics	Emerging role of liquid biopsies and NGS for biomarker discovery	Raed Samara, PhD Senior Global Product Manager, QIAGEN
1-Oct	07:30 - 08:30 AM	Melanoma Mini-Symposium	A Case Study for Immunotherapies and Targeted Therapies	Louise Perkins, PhD Chief Science Officer, Melanoma Research Alliance

1-Oct	07:30 - 08:30 AM	Targeted, precision therapies for advanced disease	Latest clinical results in oncology drug management	Salvatore J Salamone, PhD Founder and Chief Scientific Officer, Saladax Biomedical, Inc.
1-Oct	09:00 - 10:00 AM	Melanoma Mini-Symposium	Engaging the Patient in the Treatment Journey	Timothy Turnham, PhD Executive Director, Melanoma Research Foundation Shelby Moneer, MS, CHES Director of Education, Melanoma Research Foundation
1-Oct	09:00 - 10:00 AM	Progress in detection of rare cancer mutations and Implications for treatment	RNA-editing in melanoma - Case for a sensitive analysis and interpretation platform for the resolution of a diverse molecular process and likely pathogenic variants	Anika Joecker, PhD Associate Director Global Product Management NGS, QIAGEN
1-Oct	10:30 - 11:30 AM	Melanoma Mini-Symposium	How the diagnosis of melanoma is made: clinical detection/recognition and histologic/genetic assessment	Whitney High, MD, JD, M.Eng Director of Dermatopathology (Dermatology), Associate Professor, Dermatology & Pathology, University of Colorado School of Medicine
1-Oct	10:30 - 11:30 AM	Innovations in Cancer Immunotherapy	Powerful Tools for In vitro Fluorescent Imaging in Cancer Research	Jackie Carville Marketing Director at Immunochemistry Technologies, LLC
1-Oct	12:00 - 01:00 PM	Tools and Strategies for Improving Clinical trial outcomes and Predictive modeling	Can the World's First Animal Study Software to Emulate Clinical Trial Approaches Improve Clinical Outcome Predictability?	Eric Ibsen Vice President, Studylog Systems
1-Oct	12:00 - 01:00 PM	Progress in detection of rare cancer mutations and Implications for treatment	Detection and sequencing of rare mutations using mutation enrichment via COLD-PCR	Mike Makrigiorgos, PhD, DABMP Professor and Director, Division of Medical Physics and Biophysics, Director, DNA technology and SARRP pre-clinical laboratories, Brigham and Women's Hospital, Dana-Farber Cancer Institute
1-Oct	12:00 - 01:00 PM	Melanoma Mini-Symposium	Keynote Presentation (during an actual infusion!): Patient #1 - Pioneering Immunotherapy and Finding The Best, Right Treatment for Stage IV Melanoma	T.J. Sharpe Patient, Survivor, Advocate, and Author of the "Patient #1" blog
1-Oct	01:30 - 02:30 PM	Targeted, precision therapies for advanced disease	Data, Data, Everywhere - Using Complexity Analysis to find coherence in Cancer Big Data	Kenneth Buetow, PhD, FACMI Director of Computational Sciences and Informatics program for Complex Adaptive Systems and Professor in the School of Life Sciences, Arizona State University